… as an effective measure to prevent thrombus propagation and recurrence … A formal
pharmacoeconomic comparison of the two … Cost-effectiveness of ruling out deep venous …

… if they were pharmacoeconomic studies comparing more than … Table 2 summarizes the
efficacy end points for each DOAC … but superior (cost-effective) over edoxaban and dabigatran. …

… cost-effective than apixaban and dabigatran from a perspective of the health care system in
the prevention of … end points, such as the number of VTE cases avoided or life-years saved. …

… ventricular posterior wall in end diastole and increased minimum … However, many
pharmacoeconomic studies showed that in … in patients with cerebral venous thrombosis: a …

… cost-effectiveness analyses of rivaroxaban versus enoxaparin for the prevention of VTE (the
result of a venous blood clot … using rivaroxaban, which was used to prevent VTE, and it was …

… The dosage regimen of dabigatran etexilate used in this study was … Indirect cost was excluded
to prevent double counting … that the prevention of VTE using dabigatran and enoxaparin …

… was developed to evaluate the pharmacoeconomic effect of 6 … (VTE), defined as deep vein
thrombosis (DVT) and pulmonary … for the primary efficacy end point, so safety end points were …

… prevention of recurrent VTE in deep vein thrombosis (DVT). Direct non–vitamin K oral
anticoagulants are changing the practice of anticoagulation and have been used to prevent … rates, …

… prevention of VTE was estimated by analysing total costs in a … of analysis widely used in
pharmacoeconomics evaluation [28] … and secondary prevention of deep vein thrombosis and/or …

… thrombosis and pulmonary embolism, stroke prevention in non-… were continued on this
regimen until the end of the study. … One Canadian study demonstrated dabigatran to be highly cost…